Scientific deep-dive
Compounded Semaglutide Bioequivalence: What 503A Pharmacies Actually Have to Test
Compounded semaglutide isn't FDA-approved, but that doesn't mean it's untested. A close look at what 503A and 503B pharmacies are actually required to verify, and where the real quality risks live.
Compounded semaglutide became a major part of the U.S. weight-loss market during the 2022–2025 shortage, even though no compounded version is an FDA-approved drug. Vials shipped from compounding pharmacies through telehealth intermediaries, sold at a fraction of the cash price of brand-name Wegovy or Ozempic, and some clinics were still selling compounded GLP-1s months after the shortage ended.[14] The marketing on both sides of the debate is loud and confident: telehealth companies imply the molecule is identical to what Novo Nordisk sells, and Novo Nordisk implies compounded versions are unregulated and dangerous. Neither framing survives a careful look at the regulatory rules.
The honest version of the story is that compounded semaglutide sits in a deliberate carveout in federal drug law — one that has nothing to do with bioequivalence trials, never required them in the first place, and was originally written for a totally different purpose. Whether the compounded vial in a patient's refrigerator is “the same molecule” as Wegovy depends on which pharmacy made it, what salt form they sourced, what tests they ran, and whether they meet a standard most patients have never heard of. This is a walk through the actual rules and what they do and don't guarantee.[1]
Compare vetted compounded semaglutide providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
No insurance needed · HSA/FSA eligible · vetted by our editors
Collective
The lowest flat medication price if you can absorb an annual membership fee
Starting price: $59/mo (+ required membership)
Get started →Read review Collective →CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Starting price: $79/mo (“starting at” price)
Get started →Read review CoreAge Rx →Embody
Low flat-rate compounded GLP-1 pricing at every dose
Starting price: $79/mo (sale price)
Get started →Read review Embody →Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Starting price: $129/mo (starting dose)
Get started →Read review Gala →Found
Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
Starting price: $169/mo (12-month plan rate)
Get started →Read review Found →| Provider | Starting price | |
|---|---|---|
8.3Collective | $59/mo (+ required membership) | Get started → |
8.3CoreAge Rx | $79/mo (“starting at” price) | Get started → |
7.8Embody | $79/mo (sale price) | Get started → |
8.2Gala | $129/mo (starting dose) | Get started → |
8.3Found | $169/mo (12-month plan rate) | Get started → |
Why compounded semaglutide exists at all
The legal foundation for compounding sits in two sections of the Federal Food, Drug, and Cosmetic Act: section 503A, which covers traditional compounding pharmacies that fill patient-specific prescriptions, and section 503B, which created a newer category of “outsourcing facilities” that can ship larger volumes without a name on every vial. Both carveouts let pharmacies prepare drug products that are not FDA-approved, under conditions that exempt them from the new-drug application process that brand-name manufacturers go through.[1]
The catch is that, ordinarily, you can't compound a copy of a commercially available FDA-approved drug. That rule exists to prevent compounders from simply undercutting brand manufacturers on patented medications. The exception — and the entire reason compounded semaglutide became a category at all — is section 506E of the FDCA, which directs the FDA to maintain a public drug shortage list. When a drug is on that list, the prohibition against compounding copies of it is temporarily lifted. The intent was clearly to let hospitals and infusion centers keep critical drugs flowing during supply disruptions, not to stand up a parallel retail market for weight-loss injections, but the statute doesn't distinguish.[3]
Semaglutide injection products were in shortage from 2022 as Novo Nordisk struggled to keep up with Ozempic and Wegovy demand. That listing was the legal hook that made it possible for compounding pharmacies and the telehealth companies that contract with them to produce and sell semaglutide at scale. On February 21, 2025, the FDA declared the shortage resolved. It gave compounders a wind-down period: enforcement discretion for §503A pharmacies ended when a federal court denied the compounders' preliminary-injunction request on April 24, 2025, and the window for §503B outsourcing facilities closed on May 22, 2025.[2][9]
The compounders' legal challenge to that decision has failed. In Outsourcing Facilities Association v. FDA, the district court entered judgment for the FDA, and on August 27, 2026 the U.S. Court of Appeals for the Fifth Circuit affirmed. It held that any error in skipping notice-and-comment procedures was harmless and that the FDA's decision was not arbitrary or capricious.[10] In an April 1, 2026 update, the FDA noted that semaglutide is on neither the §503B bulks list nor the drug shortage list, and said a compounded product that adds an ingredient such as vitamin B12 may still be treated as “essentially a copy” of approved products when the strengths are within 10% of each other. Routine copies are not protected unless a prescriber documents that a change makes a significant difference for an individual patient.[9] The agency has also gone after marketing: on February 6, 2026 it said companies cannot claim compounded products are generic versions of, or the same as, FDA-approved drugs,[11] and on March 3, 2026 it issued 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1s.[12]
503A vs 503B: a meaningful distinction
Not all “compounding pharmacies” are the same. Section 503A pharmacies are state-licensed, regulated primarily by state boards of pharmacy, and required to fill prescriptions one patient at a time. They can't legally ship across state lines in bulk without a patient-specific prescription, and the FDA does not routinely inspect them. Their quality bar is set by the United States Pharmacopeia (USP) chapters — principally USP <797> for sterile compounding — plus whatever their state board enforces.[1][4]
Section 503B outsourcing facilities are a different animal. They register directly with the FDA, submit to FDA inspections, and are required to comply with current Good Manufacturing Practice (cGMP) regulations — the same framework that governs brand-name pharmaceutical manufacturing. They can ship in bulk to clinics and hospitals without patient-specific prescriptions. The cGMP requirement is the meaningful difference: it imposes documented batch records, validated processes, environmental monitoring, stability testing, and out-of-specification investigations that 503A pharmacies are not required to do at the same level.[1]
For a patient receiving compounded semaglutide through a telehealth provider, the question of whether the source pharmacy is 503A or 503B is one of the most consequential pieces of information about the product, and one of the hardest to extract from the marketing copy. Most large telehealth GLP-1 brands source from 503A pharmacies, because the lower regulatory overhead translates to lower per-vial cost. A smaller number source from 503B outsourcing facilities; those tend to be the ones whose pricing sits at the higher end of the compounded semaglutide market we track.
The salt-form controversy
Brand-name semaglutide — Ozempic, Wegovy, and the oral Rybelsus — is formulated as a specific molecular entity that the FDA approved on the basis of Novo Nordisk's pivotal trials. The active ingredient is the semaglutide peptide in its base form. A significant fraction of compounded semaglutide on the U.S. market is, by contrast, formulated as semaglutide sodium or semaglutide acetate — salt forms of the same peptide that have never been used in any FDA approval and never appeared in a pivotal trial. As a 2023 Clinical Diabetes report noted, when the brand manufacturer is not supplying compounding pharmacies with the active ingredient, its source is unknown.[6][7]
The FDA has flagged this directly. Its GLP-1 safety page states that semaglutide sodium and semaglutide acetate are “different active ingredients than are used in the approved drugs,” that the agency does not have information on whether they have the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for their use in compounding. Compounders argue that the peptide is the same molecule once it dissolves in solution, and that the counter-ion (sodium or acetate) is biologically inert. Pharmacologically, salt forms of the same active moiety often do behave similarly once dissolved, but regulators normally require data to show that before treating them as interchangeable. “Often” isn't a clinical trial, and there is no published head-to-head pharmacokinetic study comparing semaglutide base to semaglutide sodium or semaglutide acetate in humans at therapeutic weight-loss doses.[6]
The honest assessment is that most of the rapid weight loss being reported in the wild on compounded semaglutide is clinically consistent with what you would expect from a real GLP-1 receptor agonist hitting its target, which suggests the salt-form question is probably not a complete deal-breaker in practice. But absence of pharmacokinetic data is not evidence of equivalence, and patients deserve to know which category their product falls into.
What “bioequivalence” actually means
The word “bioequivalence” gets thrown around a lot in compounded GLP-1 marketing, almost always incorrectly. The FDA's definition is precise: two drug products are bioequivalent if they have no significant difference in the rate and extent to which the active ingredient becomes available at the site of action when administered at the same molar dose under similar conditions.[15] Operationally, that gets measured as the area under the plasma concentration-time curve (AUC) and the peak plasma concentration (Cmax), and the generic product has to match the reference product on both metrics within preset statistical limits.
Bioequivalence trials are the regulatory mechanism by which generic drugs get approved as substitutable for brand-name originators. They require dosing healthy volunteers, sampling plasma at intervals, running mass-spectrometry assays, and statistical analysis of the resulting curves. They are not cheap, but they are the cheapest path to a therapeutically substitutable copy of an existing drug.
Compounded products are not generic drugs, do not go through the abbreviated new drug application (ANDA) pathway, and by definition have not undergone bioequivalence testing. This is not a regulatory loophole or an oversight — it is the explicit structure of the compounding carveout. Compounders are not making the claim that their product is therapeutically equivalent to Wegovy in the regulatory sense, and they are not legally allowed to make that claim. The carveout exists precisely so they don't have to. The same gap exists on the tirzepatide side, where no FDA study has tested compounded tirzepatide against Zepbound for bioequivalence. Anyone marketing a compounded GLP-1 as “bioequivalent to Wegovy” is using the word in the colloquial sense (“basically the same”) rather than the regulatory sense, and the distinction matters because no compounded product on the market has the data that would actually support the regulatory claim.[6]
What 503A pharmacies actually test
If compounders aren't running bioequivalence trials, what are they testing? The required quality controls under USP <797> for sterile preparations are real and meaningful, even if they're narrower than what brand manufacturers do. A reputable 503A pharmacy compounding injectable semaglutide is required, at minimum, to perform or arrange for:
- Sterility testing under USP <71>. Cultures grown from finished product samples to verify the absence of bacterial and fungal contamination. Required before release for any sterile compound with a beyond-use date longer than the immediate dispensing window.
- Endotoxin testing under USP <85>. Bacterial endotoxins (lipopolysaccharide fragments from gram-negative bacteria) can contaminate sterile injections even when the product itself is technically sterile, because dead bacterial debris survives sterilization. Endotoxins cause fever, hypotension, and shock at very low concentrations. Pyrogen testing is one of the most important quality checks in injectable compounding.[4]
- Potency / assay testing. A high-pressure liquid chromatography (HPLC) or mass spectrometry assay to confirm the actual concentration of semaglutide in the finished vial matches the labeled concentration, within an acceptable range of the label claim.
- Identity verification. Confirmation that the active ingredient actually is semaglutide, typically via mass spectrometry of the bulk powder before compounding, and ideally again on finished product.
- Beyond-use dating studies. Stability data to support the expiration date printed on each vial, accounting for the specific formulation, container, and storage conditions used.
What 503A pharmacies do not have to test is also worth being explicit about: there is no requirement for bioavailability studies, no requirement for clinical efficacy data, no requirement for head-to-head comparison against Wegovy, no requirement for long-term stability beyond the labeled beyond-use date, and no federal requirement to report adverse events to the FDA, which the agency says likely leads to underreporting. The quality signal from a 503A pharmacy is a snapshot of identity, sterility, and potency at the moment of dispensing — nothing about clinical performance.[6]
What 503B outsourcing facilities do differently
Outsourcing facilities operating under section 503B layer cGMP requirements on top of the USP chapters. In practice that means a meaningfully thicker quality system: validated equipment cleaning protocols, written master batch records signed off by quality assurance, environmental monitoring of compounding suites, formal supplier qualification of active pharmaceutical ingredient (API) sources, stability programs that follow ICH guidelines, and FDA inspections that look like the inspections done at brand-name manufacturing sites.[1]
The result is not the same thing as an FDA-approved drug — there is still no NDA, no clinical trial data, no bioequivalence package — but the manufacturing process looks structurally similar to how brand drugs are made. For patients who care about quality assurance and are willing to pay a premium for it, sourcing from a 503B outsourcing facility is the closest thing to a brand-equivalent compounded product currently available. The trade-off is cost: 503B-sourced compounded semaglutide generally costs more than the cheapest compounded semaglutide providers sourced from 503A pharmacies.
The PCAB accreditation distinction
PCAB (the Pharmacy Compounding Accreditation Board, now part of ACHC) is a third-party accrediting body that audits compounding pharmacies against a published standard substantially more rigorous than baseline state-board licensure. PCAB accreditation is voluntary — pharmacies choose to apply, pay for the audit, and submit to ongoing inspections. The accreditation verifies that a pharmacy has documented standard operating procedures, a functional quality assurance program, trained personnel, and a track record of compliance with USP chapters and applicable state and federal regulations.[5]
It is not the same as an FDA inspection, and it does not substitute for cGMP, but it is one of the few external signals available to a patient or prescriber that a 503A pharmacy operates above the regulatory floor. PCAB accreditation status is publicly searchable through the ACHC directory; a pharmacy that claims accreditation but does not appear in the directory is a red flag, and a pharmacy that has never sought accreditation is not necessarily bad but is also not externally audited beyond what its state board requires. For a high-volume product like compounded semaglutide, where quality variability has real clinical stakes, PCAB accreditation is the single easiest filter a patient can apply.
Real-world quality concerns
The FDA has documented recurring problems with compounded semaglutide. In a July 2024 alert, it reported adverse events, some requiring hospitalization, tied to dosing errors with compounded injectable semaglutide. Most reports described patients drawing up more than the prescribed dose from a multiple-dose vial and taking five to 20 times the intended amount; confusion between milliliters, milligrams, and “units” may have contributed, and some clinicians miscalculated doses.[8] The agency's GLP-1 safety page adds concerns about salt forms, multiple-dose vials used beyond 28 days, products that arrive warm, and fraudulent products labeled with pharmacies that do not exist or did not make them. As of May 31, 2026, the FDA had received 990 adverse-event reports associated with compounded semaglutide, and it notes the true number is likely higher because 503A pharmacies are not required to report.[6]
The right way to read these reports is neither “compounded GLP-1s are reckless” nor “everything is fine.” The FDA notes that many of the adverse events reported for compounded products look like those seen with the FDA-approved versions.[6] The variance across compounders is the actual story — the ceiling is reasonable, the floor is not, and which one a patient gets depends on the specific pharmacy their provider contracts with. A secret-shopper study of 75 weight-loss clinics and medical spas in West Virginia and Oklahoma, done from August to October 2025 after the shortages ended, found that 56% offered compounded GLP-1s combined with B vitamins, and that 4 of 21 supplying facilities with licensing data were not licensed for sterile compounding.[14]
The first laboratory comparisons are also appearing, though the main study comes from the brand manufacturer. In a 2026 analysis in Pharmaceutical Research, Novo Nordisk scientists tested follow-on and compounded semaglutide and liraglutide products and found impurity profiles that differed from the originators, including amino-acid deletions or additions and unidentified impurities. When exposed to light, compounded semaglutide differed significantly from the originator in strength, total impurities, and high-molecular-weight protein levels, and in a cell-based assay some impurities showed potential to trigger an immune response. The authors were Novo Nordisk employees or shareholders, and the study measured laboratory markers, not clinical outcomes in patients.[13]
What a careful patient should ask
For a patient who has decided that compounded semaglutide is the right call — whether for cost, access, or flexibility reasons — the questions worth getting clear answers to before the first injection are concrete and answerable. None of them require a pharmacology degree, and none of them are unreasonable for a telehealth provider to address in writing.
- Which pharmacy fills the prescription, and is it a 503A or a 503B facility? The answer should be a specific pharmacy name. “Our network of partner pharmacies” is not an answer. If the provider can't or won't name the source, that is a meaningful signal.
- Is the pharmacy PCAB accredited? Verify the answer independently in the ACHC directory rather than taking the marketing copy at face value.
- What salt form of semaglutide is used? Semaglutide base is the form used in Wegovy and Ozempic. Semaglutide sodium and semaglutide acetate are salt forms the FDA says it knows of no lawful basis for using in compounding. A provider that uses a salt form, or is unwilling to state which form it sells, is a problem.[6]
- Does the pharmacy provide a certificate of analysis on each batch? A reputable compounder will produce documentation of identity, potency, and sterility testing on the specific lot the patient receives. Asking for it once is reasonable; being refused is informative.
- Who calculates the dose, and how? The answer should not be “you do, based on the instructions on the box.” A safer setup involves a clinician confirming the injection volume in writing and the pharmacy labeling each vial with the milligrams-per-milliliter concentration in plain language.
The compounded semaglutide market is going to keep existing in some form for the foreseeable future, even though federal courts have upheld the FDA's decision to end the shortage and the agency is pressing enforcement. The category isn't going away because the underlying access and cost problems with brand-name GLP-1s haven't gone away. The right response from a consumer-protection standpoint isn't to pretend the product doesn't exist or to assume it's uniformly dangerous — it's to ask the small number of questions that separate the responsible end of the market from the careless end. The information is available; the gap is between patients knowing they have the right to ask and providers being willing to answer plainly.
Frequently Asked Questions
References
- 1.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- 2.U.S. Food and Drug Administration. FDA Drug Shortages: Semaglutide Injection (status: Resolved). FDA Drug Shortages Database. 2025. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=r
- 3.U.S. Congress. Federal Food, Drug, and Cosmetic Act, Sections 503A, 503B, and 506E. 21 U.S.C. §§ 353a, 353b, 356e. 2013. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
- 4.United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. United States Pharmacopeia. 2023. https://www.usp.org/compounding/general-chapter-797
- 5.Accreditation Commission for Health Care (ACHC/PCAB). Pharmacy Compounding Accreditation Board Standards. ACHC. 2024. https://www.achc.org/pharmacy/
- 6.U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (including statements on semaglutide salt forms). FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- 7.Whitley HP, Trujillo JM, Neumiller JJ. Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages. Clin Diabetes. 2023. PMID: 37456085.
- 8.U.S. Food and Drug Administration. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products. FDA Human Drug Compounding (July 26, 2024). 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- 9.U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026). FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- 10.U.S. Court of Appeals for the Fifth Circuit. Outsourcing Facilities Association v. Food & Drug Administration, No. 25-10758 (per curiam, unpublished; filed August 27, 2026, revised September 1, 2026). U.S. Court of Appeals for the Fifth Circuit. 2026. https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
- 11.U.S. Food and Drug Administration. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs (statement, February 6, 2026). FDA Press Announcements. 2026. https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
- 12.U.S. Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (March 3, 2026). FDA Press Announcements. 2026. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
- 13.Kopp KL, Lamberth K, Schelde O, et al. Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists. Pharm Res. 2026. PMID: 42533250.
- 14.DiStefano MJ, Tilley A, Paratane D, et al. Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand. JAMA Health Forum. 2026. PMID: 42467450.
- 15.U.S. Code of Federal Regulations. 21 CFR 314.3 — Definitions (bioavailability; bioequivalence). Electronic Code of Federal Regulations (eCFR). 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-A/section-314.3
Further reading
Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
HumeCare+
GLP-1 weight loss with real-time body-composition tracking to protect muscle
Read full review →From $199/mo
Get started →Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →From $59/mo (+ required membership)
Get started →CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →From $79/mo (“starting at” price)
Get started →